Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma's Partner sanofi-aventis
The key highlights of the announcement are:
- Phase III study endpoints with Lixisenatide in diabetes successfully met in first reported study
- Improved glycemic control in T2DM patients dosed once daily as monotherapy
- Lixisenatide was generally well tolerated with no significant adverse events
- Complete study findings submitted for presentation at EASD in September 2010
- Phase III program with the combination of Lixisenatide/Lantus® expected to commence in 2010 - Lantus® is the number-one sold insulin in the world in both sales and units (source: IMS, 2009 sales)
Commenting on the announcement David Solomon, Chief Executive Officer and President of Zealand Pharma, said: "We are delighted to note today's announcement from our strong partner, sanofi-aventis, regarding the first successful Phase III results from the GetGoal study for Lixisenatide. These results represent a significant achievement for Zealand Pharma, and for patients with T2DM. We look forward to the ongoing clinical development of Lixisenatide by sanofi-aventis and are extremely excited about the future initiation of new Phase III studies of Lixisenatide in combination with Lantus® which are expected to commence later this year."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.